ARTICLE | Clinical News
PMPA: GILD began enrollment of up to 175 HIV-positive patients in a double-blind, placebo-controlled, dose-ranging Phase II trial.
September 8, 1998 7:00 AM UTC
Gilead Sciences Inc. (GILD), Foster City, Calif. Product: PMPA oral prodrug Indication: Treat HIV infection Status: GILD began enrollment of up to 175 HIV-positive patients in a double-blind, placebo...